Should I buy Sanofi stock in 2025?

What is Sanofi?

How much is the Sanofi stock?

The price of Sanofi stock is rising this week. As of now, the Sanofi ADR trades at $52.35, up 0.69% over the last 24 hours, though showing a 0.71% decline over the past week.

A low beta of 0.36 signals lower volatility than the broader market. This performance and stability make Sanofi an interesting option for Irish investors seeking both growth and income potential, particularly in less volatile blue-chip shares.

Our complete analysis on Sanofi stock

Having undertaken a rigorous review of Sanofi’s most recent quarterly performance, along with a comprehensive assessment of its stock price evolution over the past three years, our analysis utilises an integrated suite of financial metrics, technical signals, cross-market data, and competitor benchmarking—processed by proprietary valuation algorithms. The convergence of these diverse perspectives points to a stock that is both fundamentally robust and technically appealing. So, why might Sanofi once again represent a strategic entry point into the global pharmaceutical sector as we head into 2025?

Recent Performance and Market Context

Sanofi (SNY/SAN.PA) is currently trading at $52.35 USD (ADR) / €87.49 EUR (Euronext), representing a measured yet persistent upward trajectory for the year—registering a 10.05% gain over the past twelve months, and nearly 8% over the last six months. This positive performance has taken place within an evolving sectorial and macroeconomic environment marked by robust healthcare expenditure and resilient demand for innovative therapeutics.

• Q1 2025 financial results beat: Revenue surging by +10.8% to €9.895 billion, with net income up +15.9%.
• Strategic acquisition: The pending $470 million takeover of Vigil Neuroscience in May 2025, designed to strengthen Sanofi’s expanding neurology and Alzheimer’s portfolio.
• Regulatory tailwinds: Six new approvals in high-growth areas such as immunology, rare disease, and oncology, providing fresh revenue streams.

Sector-wide, the continued global focus on pharmaceutical R&D, coupled with strong demographic and regulatory trends, creates a supportive backdrop. The technology-driven evolution in drug discovery and commercialisation, combined with sustained demand across Western Europe and emerging markets, favours established leaders like Sanofi.

Technical Analysis

A granular dive into Sanofi’s technical configuration reveals a stock in an encouraging phase, with solid risk-reward characteristics for new entrants:

• Key indicators: The 14-day RSI stands at 53.44, signalling a neutral stance but leaning towards a constructive momentum profile—ample room remains before overbought territory emerges.
• MACD: Reading at 0.23, while technically a short-term sell cue, is consistent with normal consolidation phases rather than structural weakness.
• Moving averages: All major windows (20d, 50d, 100d, and 200d) sit distinctly below the current price, providing multiple converging layers of support (20d MA: $51.78; 200d MA: $51.56). Action above these levels typically marks the early stage of a new bullish trend.
• Support/resistance: $51.48 (support) and $52.64 (resistance) as Fibonacci anchors create a compressed range with upward breakout potential, particularly given the 52-week band ($45.80–$60.12).

This technical structure, confirmed by a strong “buy” consensus from leading technical models, suggests favourable short- and medium-term trajectory, with volatility remaining subdued (beta: 0.36).

Fundamental Analysis

Sanofi’s fundamentals underpin significant confidence for both current and prospective shareholders:

• Revenue and profitability: Q1 2025 saw record sales of €9.895 billion (+10.8% y/y), operating income up +20.1%, and EPS growing by +17%. Crucially, this growth outpaced market expectations, with Dupixent sales (+20.3%) and new product launches (+43.8%) as drivers.
• Attractive valuation: The company’s P/E at 18.5 (TTM) remains well within its historical average, and compares favourably among global pharma majors, especially considering the growth profile and current dividend yield of 4.23%.
• Strategic expansion: The Vigil Neuroscience acquisition positions Sanofi at the forefront of neurodegenerative R&D. Robust investment in R&D (€1.8bn, up +6.9% y/y) sustains its innovation engine.
• Structural strengths:
• Leadership in immunology with Dupixent (about 30% of total sales), a category-defining medicine.
• Balanced revenue profile: >40% US, 25% Europe, meaningful share in fast-growing emerging markets.
• Diversified product mix across pharmaceuticals, vaccines, and consumer healthcare buffers against sector-specific headwinds.
• Brand resilience: Sanofi’s reputation, global reach, and history of value creation provide a durable moat amid rising competition.

Volume and Liquidity

A healthy average daily trading volume of 2.87 million shares over the last three months confirms sustained market confidence and institutional activity. Sanofi’s substantial float ($127.76bn market cap, 1.22bn shares outstanding), combined with solid bid-ask spreads and deep order books, ensures liquidity across both retail and institutional segments. This liquidity and float configuration is highly conducive to dynamic price discovery and efficient capital allocation.

Catalysts and Positive Outlook

Multiple imminent catalysts offer clear pathways for value creation:

• Innovations and launches: Ongoing market share gains by Dupixent, the expected blockbuster trajectory for ALTUVIIIO, and fresh regulatory approvals in high-value therapy areas.
• M&A and strategic expansion: The integration of Vigil Neuroscience in H2 2025 will open new therapeutic franchises, particularly in high-unmet-need neurology.
• ESG momentum: Sustainability commitments and a strategic portfolio shift (with 70% focused on diseases exacerbated by climate and environmental issues) improve Sanofi’s profile for impact-oriented capital.
• Buyback programme: A €5bn share repurchase plan (72% already executed) underscores management’s confidence and may add significant upward pressure on EPS.
• Favourable regulatory and sector trends: The pharmaceutical sector continues to benefit from policy tailwinds, predictable reimbursement models in key geographies, and a global shift towards specialty medicines and vaccines.

Analyst sentiment remains robust, with the average target price of $65.53 USD representing 25% upside from current levels—this consensus is built on both fundamental and pipeline-driven growth expectations.

Investment Strategies

Sanofi appeals to a wide spectrum of investment strategies, delivering compelling arguments for several timeframes:

• Short-term:
• Technical consolidation just above key support ($51.48) and recent post-earnings stability creates a springboard for tactical entries.
• Any breakout above the $52.64 resistance could rapidly target new year-to-date highs.
• Medium-term:
• Ongoing integration of recent acquisitions and additional product launches forecast steady sequential growth into Q3 and Q4 2025.
• Share buyback momentum and sustained analyst upgrades can underpin further rerating.
• Long-term:
• Sanofi’s reinforced position in immunology and rare disease, combined with its robust innovation pipeline and leadership in high-growth therapy areas, build a platform for multi-year compounding.
• The company’s attractive dividend, resilient FCF generation, and low beta suit balanced, defensive portfolios seeking exposure to healthcare megatrends.

Ideal positioning, in our view, sits close to current technical lows, capitalising on both fundamental catalysts and the potential for a new bullish cycle as new product ramp-ups and acquisitions start to reflect in earnings.

Is it the Right Time to Buy Sanofi?

Sanofi combines the hallmarks of an excellent buy-side candidate: strong and accelerating revenue, consistent outperformance versus expectations, a robust innovation pipeline, and a valuation that remains highly attractive relative to its growth potential. Technical indicators suggest the stock may be entering a new bullish phase, with both structural support and imminent catalysts pointing to further upside. The broad strategic expansion—across geographies, product lines, and therapeutic areas—provides diversification and future-proofing, while active share buybacks and a quality dividend add meaningful shareholder value.

For investors searching for stability combined with opportunity in the global pharmaceutical and healthcare sector, Sanofi seems to represent an excellent opportunity at current levels, underpinned by financial strength, innovation and sustained market leadership. As we look towards 2025, the fundamentals amply justify renewed interest—the stock’s momentum and pipeline-driven catalysts could well make this period an optimal entry point.

In the current environment, Sanofi’s profile stands out as a uniquely balanced blend of resilience and growth—a stock that may well define the next phase of leadership in global healthcare portfolios.

How to buy Sanofi stock in IE?

Buying Sanofi stock online has never been easier or more secure for Irish investors. With a regulated online broker, you can acquire Sanofi shares quickly, taking advantage of robust investor protections. You have two main options: buying the shares outright (known as spot or cash buying) or trading Sanofi via CFDs (Contracts for Difference), which allow you to speculate on the price movement with leverage. Each method has its advantages and costs. If you’re not sure which route to take, you’ll find a detailed broker comparison further down this page to help you make an informed choice.

Spot buying

A cash purchase means you buy Sanofi shares outright on the stock market (e.g., on the NASDAQ, where Sanofi is listed as SNY in USD). This makes you the owner of the shares, entitling you to any dividends and voting rights. Irish brokers typically charge a fixed commission per trade, often around $5–$10, regardless of the order size.

Example

If the Sanofi ADR share price is $52.35 and you invest $1,000, you can buy about 19 shares (since $1,000 - $5 fee = $995, $995 ÷ $52.35 ≈ 19 shares).
✔️ Gain scenario: If the price rises by 10%, your 19 shares would now be worth about $1,100.
Result: +$100 gross gain, or +10% on your investment (not accounting for any taxes or minor currency conversion costs).

Trading via CFD

A CFD (Contract for Difference) lets you trade Sanofi shares’ price movements without owning the actual shares. This is popular for short-term strategies and offers the ability to use leverage, but you won’t receive dividends or voting rights. Brokers make money mainly through the spread (the difference between buy and sell prices) and typically charge a daily overnight financing fee if you hold leveraged positions open overnight.

Example

You open a CFD on Sanofi with $1,000 and use 5x leverage, so your market exposure equals $5,000.
✔️ Gain scenario: If Sanofi rises by 8%, your position would earn 8% × 5 = 40%, or +$400 (on your $1,000 at risk, excluding spread and overnight fees). Remember, leverage magnifies both gains and losses.

Final advice

It’s essential to carefully compare brokers’ fees, spreads, platforms, and conditions before investing, as these can vary significantly and impact your returns. Your choice between cash buying and CFDs should reflect your investment goals, risk appetite, and time horizon. For a side-by-side comparison of trusted brokers available in Ireland, check out the comparison table further down this page.

Our 7 tips for buying Sanofi stock

The latest news about Sanofi

Sanofi posted robust Q1 2025 results, outperforming analyst expectations with double-digit revenue and profit growth. Driven largely by the success of its flagship medicine Dupixent, which contributed €3.5 billion in sales (+20.3%), and strong momentum from new drug launches (+43.8%), Sanofi reported quarterly revenue of €9.895 billion (+10.8%) and a net profit of €2.212 billion (+15.9%). The company demonstrated resilience in its vaccine segment (+11.4%) and a continued rise in earnings per share (€1.79, +17%). This performance strengthens Sanofi’s profile as a stable and growing multinational, particularly notable for investors in Ireland monitoring European pharmaceutical sector strength.

Analysts maintain a strong buy consensus with a target price significantly above current levels, supported by technical and fundamental indicators. Sanofi's stock is trading at $52.35 (ADR) on NASDAQ and €87.49 on Euronext, with a modest one-week retreat (-0.71%) but a steady 12-month gain (+10.05%). Key technical signals, including all major moving averages, indicate a continued buy trend, and the latest analyst consensus points to a 25% potential upside, with a $65.53 average price target. The company also boasts a high dividend yield of 4.23% and low beta (0.36), which is particularly attractive to Irish institutional investors seeking defensive assets with stable returns.

Sanofi has advanced its innovation pipeline with six new regulatory approvals and a strategic acquisition targeting neurology and Alzheimer’s therapies. In the past quarter, Sanofi secured six regulatory approvals across immunology, rare diseases, and oncology—critical therapeutic areas with strong demand in Ireland and across the EU. Additionally, Sanofi announced the $470 million acquisition of Vigil Neuroscience, expected to close in Q3 2025, which will expand its footprint in high-growth neurological markets. This move potentially enhances Sanofi’s relevance in central nervous system indications, a growing segment in Irish healthcare and clinical research.

Sanofi’s positive 2025 guidance and accelerated buyback program underscore confidence in future performance and shareholder returns. The company confirmed its 2025 sales guidance (mid to high single-digit growth at constant exchange rates) and expects low double-digit growth in earnings per share. Notably, Sanofi is actively returning capital, having already executed 72% of its €5 billion share buyback program. With over 25% of total revenue coming from Europe, Irish investors benefit directly from Sanofi's stability and continuing commitment to shareholder value in the region.

Sanofi’s diversification and ongoing R&D investments reinforce its competitive position in Europe, with a balanced portfolio relevant to the Irish market. Sanofi’s portfolio spans specialty medicines, vaccines, and consumer healthcare, with a well-balanced 25% of its revenues generated in Europe. The firm invested €1.8 billion in R&D in Q1 2025 (+6.9%), supporting future pipeline development—including treatments for conditions with high prevalence in Ireland, such as autoimmune diseases and allergies. This strategic focus on research and a diversified product base underpins Sanofi’s sustained growth outlook and mitigates risks linked to emerging regulatory environments.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.